Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Inclusion Criteria:

Adults with established, pathologically confirmed diagnoses of newly diagnosed, poor-risk Acute Myeloid Leukemia(AML) including de novo and secondary Acute Myeloid Leukemias but excluding newly diagnosed acute progranulocytic leukemia (APL, M3) will be considered eligible for study
ECOG performance status 0-2
Patient must be able to give informed consent
Serum creatinine =< 2.0
ALT, AST =< 5 x upper limit of normal
Bilirubin =< 2.0 mg/dl
Left ventricular ejection fraction >= 45%

Newly diagnosed AML, subtypes M0,1,2,4-7 but excluding M3 (APL) with poor-risk features, including:

Age > 50 years, or age > 18 years with one or more of the following criteria:

Antecedent hematologic disorder including myelodysplasia (MDS)-related AML (MDS/AML) and prior myeloproliferative disorder (MPD)
Treatment-related AML
AML with trilineage dysplasia (AML-TLD)
Adverse cytogenetics (defined as -5/-5q; -7/-7q; abnormal 3q, 9q, 11q, 20q, 21q or 17p; t(6;9); t(9;22); trisomy 8; trisomy 13, complex karyotypes (>= 3 unrelated abnormalities)

Exclusion Criteria:

Patients who have received hydroxyurea alone or have received non-cytotoxic therapies previously for MDS or MPD (e.g., thalidomide or lenalidomide, interferon, cytokines, low-dose 5-azacytidine, low-dose cytoxan) will be eligible for this trial
Any previous treatment with flavopiridol
Concomitant chemotherapy, radiation therapy, or immunotherapy
Hyperleukocytosis with >= 50,000 blasts/uL; leukapheresis or hydroxyurea may be used immediately prior to study drug administration for cytoreduction; must be stopped 24 hours before first dose of Flavopiridol
Acute Progranulocytic Leukemia (APL, M3)
Active CNS leukemia
Active, uncontrolled infection; patients with infection under active treatment and controlled with antibiotics are eligible
Presence of other life-threatening illness
Patients with mental deficits and/or psychiatric history that preclude them form giving informed consent or from following protocol
Pregnant and nursing patients are excluded